Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Age-related decrease in B12 absorption
Zeng Z, Shan H, Lin M, et al
Limitations of the Research Despite promising animal studies, key limitations remain: Human studies are sparse: Most research is conducted in rodents with few clinical trials
US$ 27.12
)
US$ 27.68
US$ 28.40
US$ 29.24
US$ 20.64
